Alan I. Green, MD
Chair and Professor of Psychiatry
Professor of Molecular and Systems Biology
Chair, Department of Psychiatry
Director, SYNERGY: Dartmouth Clinical and Translational Science Institute
Associate Dean for Clinical and Translational Science, Geisel School of Medicine at Dartmouth
Raymond Sobel Professor of Psychiatry, Geisel School of Medicine at Dartmouth
Molecular and Systems Biology
Columbia College, A.B. 1965
The Johns Hopkins University School of Medicine, M.D. 1969
Neuroscience Center at Dartmouth
Program in Experimental and Molecular Medicine
Psychopharmacology Research Group
Geisel School of Medicine at Dartmouth, Department of Psychiatry
SYNERGY (Dartmouth Center for Clinical and Translational Science)
Neuroscience Center at Dartmouth
PEMM at Dartmouth
Department of Psychiatry
Geisel School of Medicine at Dartmouth
DHMC 1 Medical Center Drive
Lebanon NH 03756
Schizophrenia and comorbid substance use disorder: neuropharmacology, neuroimaging and treatment development
Medication development for addiction
Brain reward circuitry
Early intervention in schizophrenia
Dr. Green's research program, which involves clinical and neurobiological studies of patients with schizophrenia, particularly those with co-occurring substance use disorders, medication development studies for patients with alcoholism, and studies of alcohol drinking animals, has been funded by a series of grants from NIH, NARSAD and industry. He and his colleagues have proposed a neurobiological model suggesting that co-occurring substance use disorder in patients with schizophrenia relates, at least in part, to deficiencies in dopamine-mediated brain reward circuits. Data from his group have suggested that the novel antipsychotic medication clozapine limits alcohol and other substance use in these patients; he has proposed that the unique effects of clozapine in these patients relates to the mechanism of action of the drug, including its effects in brain reward circuits. On-going studies are continuing to probe the optimal psychopharmacological strategies for patients with co-occurring disorders through clinical trials, neuroimaging studies in humans, and a series of pharmacologic, neuroimaging and neurostimulation investigations in animals.
Rotations and Thesis Projects:
1) Medication development for alcohol drinking in rodents.
2) Neuroimaging and brain reward circuitry in schizophrenia.
R21DA044501 (Green) 09/01/2017 – 08/31/2020
Reward circuit dysfunction, substance use disorder, and schizophrenia: a preclinical fMRI-based connectivity study
The goal of this proposal is to begin to bridge the gap between clinical studies and our theoretical formulation of the basis of substance use in schizophrenia through study of fMRI connectivity in the NVHL rat.
R01DA034699 ( Green) 09/01/2013 – 03/31/2020
Cannabis, schizophrenia and reward: self-medication and agonist treatment?
Using neuroimaging techniques, as well as behavioral measures of reward responsiveness, this study aims to assess the effects of smoked cannabis and oral dronabinol (THC) on the brain reward circuit in patients with schizophrenia and co-occurring cannabis use disorder, as well as in patients with cannabis use disorder alone.
UL1 TR001086 (Green) 09/26/2013 – 04/30/2020
SYNERGY| The Dartmouth Clinical and Translational Science Institute
SYNERGY| The Dartmouth Clinical and Translational Science Institute (CTSA) seeks to promote and substantially strengthen Dartmouth's basic, clinical, translational and outcomes research potential.
UH2DA041713 (Marsch/Poldrack) 09/15/2015 – 08/31/2020
NIH/NIDA (via NIH Common Fund)
Applying Novel Technologies and Methods to Inform the Ontology of Self-Regulation
This study will examine putative targets (processes) of behavior change within the self-regulation mechanism domain across contexts, populations, and assays – in 3 primary levels of analysis: (1) psychological (e.g., constructs such as self-efficacy; emotion regulation; response inhibition), (2) behavioral (e.g., tasks of reward responsiveness; temporal horizon), and (3) biological (structural and functional MRI of key neural circuitry).
U01 TR002628 (Lenert) 08/06/2019 – 06/30/2024
Adapting the ACT Network to Address the Opioid Epidemic Through Infrastructure for ED-based Trials.
This study, involving investigators from Medical University of South Carolina, University of California, San Diego, University of Kentucky and Dartmouth, will assess the nature of opioid use in emergency departments as a base for further cross-CTSA studies.
Graduate and Medical Pharmacology
Neuroscience of Psychiatric Disorders
Alan I. Green, M.D. is the Raymond Sobel Professor of Psychiatry, Professor of Molecular and Systems Biology, and Chair of the Department of Psychiatry at Geisel School of Medicine at Dartmouth.
Director, Dartmouth SYNERGY, The Dartmouth Clinical and Translational Science Institute.
He received his B.A. from Columbia College and his M.D. degree from the Johns Hopkins University School of Medicine. Following an internship in medicine at the Beth Israel Hospital in Boston, he was a research associate at the National Institute of Mental Health and was Director of Biomedical Research at the Special Action Office for Drug Abuse Prevention in the Executive Office of the President. He did his psychiatry residency and a clinical research fellowship at the Harvard-based Massachusetts Mental Health Center. He joined the Harvard faculty in 1984 and was Director of the Commonwealth Research Center at Harvard Medical School from 1987 until 2002. He joined the Geisel School of Medicine's Department of Psychiatry as Professor and Chairman in November 2002, and he became Director of Dartmouth SYNERGY in 2012. He has been a highly productive and active investigator, has received peer-reviewed funding throughout his career, has mentored over 45 trainees, and is the author of more than 300 papers and abstracts.
Dr. Green has been the primary research mentor for over 45 predoctoral and postdoctoral trainees. At present, he is the primary mentor for a number of junior investigators, post-doctoral research fellows, graduate students, and undergraduates.
Henricks AM, Dwiel LL, Deveau NH, Simon AA, Ruiz-Jaquez MJ, Green AI, Doucette WT. Corticostriatal Oscillations Predict High vs. Low Drinkers in a Rat Model of Limited Access Alcohol Consumption. Frontiers in Systems Neuroscience. 2019, Epub August 13, 2019 (view details on MedLine)
Whitton AE, Green AI, Pizzagalli DA, Roth RM, Williams JM, Brunette MF. Potent dopamine D2 antagonists block the reward-enhancing effects of nicotine in smokers with schizophrenia. Schizophrenia Bulletin, 2019, Epub ahead of print (view details on MedLine)
Khokhar J, Green AI. Unique Effects of Clozapine: A Pharmacological Perspective. Advances in Pharmacology, 2018. 82: 137-162. (view details on MedLine)
Doucette W, Dwiel L, Boyce JE, Simon AA, Khokhar JY, Green AI. Machine learning based classification of deep brain stimulation outcomes in a rat model of binge eating using ventral striatal oscillations. Frontiers in Psychiatry, 2018. 9 (336): 1-11. (view details on MedLine)
Green AI, Khokhar J. Addiction and schizophrenia: a translational perspective. Schizophrenia Research, 2018. 194: 1-3. (view details on MedLine)
Whitfield-Gabrieli S, Fischer AS, Roth RM, Brunette MF, Green AI. Understanding marijuana’s effects on functional connectivity of the default mode network in patients with schizophrenia and co-occurring cannabis use disorder: a pilot investigation. Schizophrenia Research, 2018. 194:70-77. (view details on MedLine)
Khokhar J, Dwiel LL, Henricks AM, Doucette WT, Green AI. The link between schizophrenia and substance use disorder: a unifying hypothesis. Schizophrenia Research, 2018. 194: 78-85. (view details on MedLine)
Khokhar J, Green AI. Effects of iloperidone, combined with desipramine, on alcohol drinking in the Syrian golden hamster. Neuropharmacology, 2016. 105:25-34. PMC4873404 (view details on MedLine)
Doucette WT, Khokhar JY, Green AI. Nucleus accumbens deep brain stimulation in a rat model of binge eating. Translational Psychiatry, 2015. 5:e695. PMC5068592 (view details on MedLine)
Green AI, Brunette MF, Dawson R, Buckley P, Hafez H, Herz M, Narasimhan M, Noordsy D, O’Keefe C, Sommi RW, Weeks M. Long-acting Injectable vs. Oral Risperidone for Schizophrenia and Co-occurring Alcohol Disorder: A Randomized Trial. The Journal of Clinical Psychiatry, 2015. 76(10):1359-1365. (view details on MedLine)